Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 23, 2025 07:00 ET | Source: Castle Biosciences, Inc.

FDA Grants Breakthrough Device Designation to Castle Biosciences’ DecisionDx®-Melanoma Test

Castle announced that its DecisionDx®-Melanoma test has been granted Breakthrough Device designation from the U.S. Food and Drug Administration (FDA).
May 29, 2025 16:30 ET | Source: Castle Biosciences, Inc.

New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes

Castle will present new data aimed at enhancing the clinical management of patients with cutaneous melanoma and uveal melanoma at ASCO 2025.
May 07, 2025 07:00 ET | Source: Castle Biosciences, Inc.

Castle Biosciences Celebrates Skin Cancer Awareness Month

Castle continues its ongoing patient advocacy partnerships and highlights cancer journey to drive education and awareness for Skin Cancer Awareness Month
April 30, 2025 17:00 ET | Source: Castle Biosciences, Inc.

New Study Shows Castle Biosciences’ DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity

Castle announced the publication of a new study demonstrating DecisionDx-Melanoma outperforms AJCC staging and the CP-GEP test.
April 28, 2025 07:00 ET | Source: Castle Biosciences, Inc.

DecisionDx®-Melanoma Test Ordered More Than 200,000 Times for Patients Diagnosed with Cutaneous Melanoma

Castle announces its achievement of surpassing a significant milestone of 200,000 DecisionDx-Melanoma clinical test orders.
April 25, 2025 16:15 ET | Source: Castle Biosciences, Inc.

New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis

Castle Biosciences will share new data intended to improve the care of patients with cutaneous and uveal melanoma at the AACR Annual Meeting 2025.
April 03, 2025 07:00 ET | Source: Castle Biosciences, Inc.

Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences’ DecisionDx®-Melanoma Test

Castle announced the recent publication of prospective data demonstrating the significant impact of DecisionDx-Melanoma on SLNB decision-making.
April 01, 2025 16:30 ET | Source: Castle Biosciences, Inc.

Castle Biosciences to Present New Data at EADO Supporting the Clinical Value of the DecisionDx®-Melanoma Test in Guiding Risk-Aligned Management of Patients with Melanoma

Castle will present data on DecisionDx-Melanoma at the 11th World Congress of Melanoma and 21st European Association of Dermato-Oncology (EADO) Congress.